Order Article Reprints

Gil M, Winiarczyk K, Krawczyk P, Wojas-Krawczyk K, Łomża-Łaba A, Obara A, Gajek Ł, Reszka K, Tysarowski A, Buczkowski J, et al. Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers. Cancers. 2025; 17(7):1253. https://doi.org/10.3390/cancers17071253

Gil, Michał, Kinga Winiarczyk, Paweł Krawczyk, Kamila Wojas-Krawczyk, Aleksandra Łomża-Łaba, Adrian Obara, Łukasz Gajek, Katarzyna Reszka, Andrzej Tysarowski, Jarosław Buczkowski, and et al. 2025. "Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers" Cancers 17, no. 7: 1253. https://doi.org/10.3390/cancers17071253

Gil, M., Winiarczyk, K., Krawczyk, P., Wojas-Krawczyk, K., Łomża-Łaba, A., Obara, A., Gajek, Ł., Reszka, K., Tysarowski, A., Buczkowski, J., Chmielewska, I., Jankowski, T., Szuba-Gil, M., Strzemski, M., Kowalski, D. M., Milanowski, J., & Krzakowski, M. (2025). Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers. Cancers, 17(7), 1253. https://doi.org/10.3390/cancers17071253